Review
Nature Reviews Cancer 5, 921-929 (December 2005) | doi:10.1038/nrc1753
Oncogenic PI3K deregulates transcription and translation
Andreas G. Bader1, Sohye Kang1, Li Zhao1 & Peter K. Vogt1 About the author
Abstract
There have long been indications of a role for PI3K (phosphatidylinositol 3-kinase) in cancer pathogenesis. Experimental data document a requirement for deregulation of both transcription and translation in PI3K-mediated oncogenic transformation. The recent discoveries of cancer-specific mutations in PIK3CA, the gene that encodes the catalytic subunit p110
of PI3K, have heightened the interest in the oncogenic potential of this lipid kinase and have made p110 an ideal drug target.
- View At a Glance
Author affiliations
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Correspondence to: Peter K. Vogt1 Email: pkvogt@scripps.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNature Cell Biology Article (01 Sep 2002)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysNature Medicine Article (01 Jun 2004)
See all 33 matches for Research